Liver Volume as a Predictor of Functional Improvement Post-DAA Treatment

Transplantation

Volumn 102, Issue 2, 2018, Pages e74-e81

  Di Maira, Tommaso ^a   Torregrosa, Asunción ^a   Navarro, Vicente ^a   Sánchez, Daniel ^a   Fornés, Victoria ^b   Berenguer, Marina ^a,c  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIRECT ANTIVIRAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY SURFACE; CHILD PUGH SCORE; CLINICAL ARTICLE; FEMALE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER WEIGHT; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPLEEN WEIGHT; SUSTAINED VIROLOGIC RESPONSE; LIVER; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

AGED; ANTIVIRAL AGENTS; BODY SURFACE AREA; FEMALE; HEPATITIS C; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 85041616450     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001990     Document Type: Article

References (34)

1. Singal AG Volk ML Jensen D. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010; 8: 280-288,. 288.e1.
2. van der Meer AJ Veldt BJ Feld JJ. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012; 308: 2584-2593.
3. Bunchorntavakul C Reddy KR. Treat chronic hepatitis C virus infection in decompensated cirrhosis-pre-or post-liver transplantation? The ironic conundrum in the era of effective and well-Tolerated therapy. J Viral Hepat. 2016; 23: 408-418.
4. Ozaki K Matsui O Kobayashi S. Selective atrophy of the middle hepatic venous drainage area in hepatitis C-related cirrhotic liver: morphometric study by using multidetector CT. Radiology. 2010; 257: 705-714.
5. Zhou XP Lu T Wei YG. Liver volume variation in patients with virus-induced cirrhosis: findings on MDCT. AJR Am J Roentgenol. 2007; 189: W153-W159.
6. Ozaki K Matsui O Kobayashi S. Morphometric changes in liver cirrhosis: Aetiological differences correlated with progression. Br J Radiol. 2016; 89: 20150896.
7. De Franchis R. Noninvasive diagnosis of esophageal varices: is it feasible? Am J Gastroenterol. 2006; 101: 2520-2522.
8. Giannini E Botta F Borro P. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut. 2003; 52: 1200-1205.
9. Berzigotti A Seijo S Arena U. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology. 2013; 144: 102-111.
10. Schindl MJ Redhead DN Fearon KC. The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection. Gut. 2005; 54: 289-296.
11. Kishi Y Abdalla EK Chun YS. Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg. 2009; 250: 540-548.
12. Shirabe K Shimada M Gion T. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg. 1999; 188: 304-309.
13. Schneider PD. Preoperative assessment of liver function. Surg Clin North Am. 2004; 84: 355-373. Review.
14. Urata K Kawasaki S Matsunami H. Calculation of child and adult standard liver volume for liver transplantation. Hepatology. 1995; 21: 1317-1321.
15. Vauthey JN Abdalla EK Doherty DA. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl. 2002; 8: 233-240.
16. Ishak K Baptista A Bianchi L. Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22: 696-699.
17. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015; 63: 237-264.
18. Mazzaferro V Regalia E Doci R. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334: 693-699.
19. American Association of Clinical Endocrinologist/American College of Endocrinology (AACE/ACE) Obesity Task Force. AACE/ACE Position statement on the prevention, diagnosis, and treatment of obesity. Endocr Pract. 1998; 4: 297.
20. Terrault N Berenguer M Strasser S. International liver transplant society consensus statement on hepatitis C management in liver transplant recipients. Transplantation. 2017; 101: 956-967.
21. Manns M Samuel D Gane EJ; SOLAR-2 investigators. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: A multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016; 16: 685-697.
22. Mandorfer M Kozbial K Schwabl P. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016; 65: 692-699.
23. Foster GR Irving WL Cheung MC. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016; 64: 1224-1231.
24. Poordad F Schiff ER Vierling JM. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with, advanced cirrhosis or post-Transplant recurrence: ALLY-1 study. J Hepatol. 2015; 62: S261-S262.
25. Belli LS Berenguer M Cortesi PA; European Liver and Intestine Association (ELITA). Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol. 2016; 65: 524-531.
26. Charlton M Everson GT Flamm SL. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV Infection in patients with advanced liver disease. Gastroenterology. 2015; 149: 649-659.
27. Curry MP O'Leary JG Bzowej N. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015; 373: 2618-2628.
28. Foster GR McLauchlan J Irving W. Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3. J Hepatol. 2015; 62 (Suppl 2): S190-S191.
29. Yoneyama T Asonuma K Okajima H. Coefficient factor for graft weight estimation from preoperative computed tomography volumetry in living donor liver transplantation. Liver Transpl. 2011; 17: 369-372.
30. Kokudo T Hasegawa K Uldry E. A new formula for calculating standard liver volume for living donor liver transplantation without using body weight. J Hepatol. 2015; 63: 848-854.
31. Sakamoto S Uemoto S Uryuhara K. Graft size assessment and analysis of donors for living donor liver transplantation using right lobe. Transplantation. 2001; 71: 1407-1413.
32. Kubota K Makuuchi M Kusaka K. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology. 1997; 26: 1176-1181.
33. Farges O Belghiti J Kianmanesh R. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 2003; 237: 208-217.
34. Schnitzbauer AA Lang SA Goessmann H. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012; 255: 405-414.